Introduction
============

Lung cancer is the most common cause of cancer-related death worldwide, with non-small-cell lung cancer (NSCLC) being the major histological subtype of this malignancy. Both experimental and clinical studies have identified many molecules that contribute to the various biological behaviors of malignant tumors including NSCLC. Platinum-based chemotherapy regimens are the standard first-line treatment for individuals with advanced NSCLC who do not harbor identifiable driver oncogenes, such as mutant forms of the epidermal growth factor receptor gene or rearrangements of the anaplastic lymphoma kinase gene. However, the efficacy of such regimens has reached a plateau.[@b1-tcrm-11-1701]--[@b5-tcrm-11-1701]

Vascular endothelial growth factor (VEGF), a mitogen specific for endothelial cells, is the major regulator of angiogenesis in normal and malignant tissue.[@b6-tcrm-11-1701] Increased expression of VEGF has been detected in NSCLC and is associated with poor prognosis.[@b7-tcrm-11-1701] Preclinical studies showed that a mouse monoclonal antibody specific for VEGF inhibited the growth of human tumor xenografts when administered alone or together with chemotherapy.[@b8-tcrm-11-1701],[@b9-tcrm-11-1701] A humanized variant of this antibody, bevacizumab, has been extensively investigated in individuals with various types of solid tumor including NSCLC. Two large randomized Phase III studies (Eastern Cooperative Oncology Group 4599 and Avastin in Lung) found that bevacizumab provided a statistically significant benefit when combined with chemotherapy compared with chemotherapy alone in patients with advanced nonsquamous NSCLC.[@b10-tcrm-11-1701],[@b11-tcrm-11-1701] On the basis of these findings, bevacizumab-plus-cytotoxic chemotherapy has become a standard treatment option for first-line therapy in patients with advanced nonsquamous NSCLC. Given the proof of concept that targeting of angiogenesis is an effective strategy for the treatment of NSCLC; several angiogenesis inhibitors are now in development for this condition.

Nintedanib (BIBF 1120) is a potent, oral, and broadly active small-molecule tyrosine kinase inhibitor with median inhibitory concentrations in the low nanomolar range: 13--34 nmol/L for VEGF receptors 1--3; 59 nmol/L and 65 nmol/L for platelet-derived growth factor receptors α and β, respectively; 37--108 nmol/L for fibroblast growth factor receptors 1--3; and 26 nmol/L for Flt3. It is also active against members of the Src family of tyrosine kinases such as Lck, Lyn, and Src.[@b12-tcrm-11-1701] In preclinical studies, nintedanib achieved sustained blockade of VEGF receptor 2 (VEGFR2) and induced marked inhibition of tumor growth in xenograft models of human renal cell, colorectal, ovarian, and prostate carcinoma as well as NSCLC.[@b12-tcrm-11-1701] Strategies deployed to inhibit VEGF signaling in preclinical studies have thus been investigated in clinical trials of nintedanib for NSCLC.

Nintedanib monotherapy
======================

Phase I trials
--------------

A dose-escalation Phase I study was conducted in German patients with advanced solid tumors to determine the maximum tolerated dose (MTD) of nintedanib as well as to evaluate the safety of continuous once- or twice-daily treatment with the drug ([Table 1](#t1-tcrm-11-1701){ref-type="table"}).[@b13-tcrm-11-1701] A total of 25 and 36 patients received nintedanib at a dose of 50--450 mg once daily or 150--300 mg twice daily, respectively, in 4-week cycles each followed by a 1-week washout. Dose-limiting toxicities (DLTs) were apparent in one of the eight patients treated with 200 mg once daily (elevation of aspartate aminotransferase \[AST\] and γ-glutamyl transpeptidase \[γ-GT\]), in one of the six patients treated with 250 mg once daily (reduction in the number of CD4^+^ lymphocytes), and in two of the five patients treated with 300 mg once daily (elevation of AST and γ-GT in one and of alanine aminotransferase \[ALT\] and AST in the other). DLTs also developed in one of the six patients treated with 200 mg twice daily (reduction in the number of CD4^+^ lymphocytes), in one of the 13 patients treated with 250 mg twice daily (nausea), and in four of the five patients treated with 300 mg twice daily (nausea and vomiting; elevation of ALT and AST; elevation of ALT, AST, and γ-GT; or reduction in the number of CD4^+^ lymphocytes and elevation of γ-GT). All DLTs were fully reversible after treatment discontinuation. The MTD for both once- and twice-daily dosing was thus 250 mg.

Another dose-escalation Phase I study was performed to determine the MTD and tolerability of nintedanib given on a twice-daily schedule in Japanese patients with advanced refractory solid tumors ([Table 1](#t1-tcrm-11-1701){ref-type="table"}).[@b14-tcrm-11-1701] Twenty-one patients -- including 14 individuals with colorectal cancer, one with NSCLC, and one with small-cell lung cancer -- were treated with nintedanib at doses of 150 mg, 200 mg, or 250 mg twice daily. None of the three patients treated with 150 mg twice daily experienced a DLT, whereas DLTs occurred in three of the 12 patients who received 200 mg twice daily and in three of the six patients who received 250 mg twice daily. All of the DLTs consisted of elevation of liver enzymes (ALT, AST, or γ-GT increases of grade 3 or 4) in the absence of a relevant bilirubin increase, and they were fully reversible on cessation of treatment. Therefore, nintedanib was found to have an acceptable tolerability profile for Japanese patients with advanced solid tumors at doses up to 200 mg twice daily, which was determined as the MTD. The MTD for Japanese subjects (200 mg twice daily) was thus lower than that for European patients (250 mg twice daily). Baseline and posttreatment levels of circulating CD117 (c-KIT)-positive bone-marrow-derived progenitor cell subsets as well as of plasma soluble VEGFR2 (sVEGFR2) were evaluated as potential biomarkers for the pharmacodynamics and dose--response relation of nintedanib. Levels of circulating CD117^+^ bone-marrow-derived progenitors and plasma sVEGFR2 decreased significantly during the treatment in all nintedanib dose cohorts, indicating that they might be associated with target inhibition by nintedanib.

Ethnic variation in the MTD of nintedanib
-----------------------------------------

Liver toxicity featured prominently among DLTs of ninte-danib monotherapy in both Japanese and European patients enrolled in Phase I trials, with such toxicity occurring at a greater frequency in the former patients than in the latter treated with the same doses ([Table 1](#t1-tcrm-11-1701){ref-type="table"}).[@b13-tcrm-11-1701],[@b14-tcrm-11-1701] These results led to a difference in the MTD of nintedanib monotherapy between European (250 mg twice daily) and Japanese (200 mg twice daily) patients. Pharmacokinetic differences may account for this difference in MTD. An analysis of nintedanib pharmacokinetics at steady state revealed that the mean maximal concentration (*C*~max~) in plasma was 67.6 ng/mL and that the area under the curve was 423 ng·hour/mL in Japanese patients treated with 200 mg twice daily, with these values being much higher than those for German patients also treated with 200 mg twice daily (*C*~max~ of 44.9 ng/mL and area under the curve of 303 ng·hour/mL). The difference in body size between Japanese and European patients may underlie these pharmacokinetic differences. Indeed, in the Phase I trial of nintedanib monotherapy in Japanese, three of the four patients with a body surface area (BSA) of \<1.5 m^2^ in the 200 mg twice daily cohort developed DLTs (hepatic enzyme elevations of grade 3), whereas DLTs were not apparent in the eight patients with a BSA of ≥1.5 m^2^ treated with the same dose. Similar findings have been reported for patients treated with sunitinib or imatinib. Retrospective analysis of the relation between BSA and sunitinib toxicity in patients with metastatic renal cell cancer thus found that a low BSA was associated with a higher incidence of DLTs, which were retrospectively defined as any toxicity leading to a dose reduction or treatment discontinuation and included asthenia, stomatitis, proteinuria, and thrombotic microangiopathy.[@b15-tcrm-11-1701] In addition, a Phase III trial comparing the efficacy and safety of imatinib with those of interferon-α plus low-dose cytarabine in patients with chronic myeloid leukemia positive for the Philadelphia chromosome found a weak inverse correlation between steady-state trough levels of imatinib and BSA.[@b16-tcrm-11-1701] These previous studies provided valuable information for the prediction of nintedanib toxicity, with patients of small physical size, who required careful assessment of liver function during treatment, undergoing nintedanib therapy.

Combination treatment with nintedanib
=====================================

Nintedanib in combination with pemetrexed
-----------------------------------------

Given the encouraging results obtained in Phase I trials of nintedanib monotherapy, a Phase I study was conducted at two sites in the USA and Canada to assess the MTD, safety, and tolerability of nintedanib in combination with pemetrexed in patients with recurrent advanced NSCLC who had previously been treated with one platinum-based chemotherapeutic regimen ([Table 2](#t2-tcrm-11-1701){ref-type="table"}).[@b17-tcrm-11-1701] Patients received a standard dose of pemetrexed (500 mg/m^2^) on day 1 followed by oral nintedanib twice daily on days 2--21. Twenty-six patients were treated with nintedanib at doses of 100 mg, 150 mg, 200 mg, or 250 mg twice daily. DLTs occurred in one of the six patients treated with 100 mg twice daily, in one of the six treated with 150 mg twice daily, in three of the 12 treated with 200 mg twice daily, and in both of the two treated with 250 mg twice daily. Nintedanib at a dose of 200 mg twice daily was thus found to be the recommended dose for continuous daily treatment in combination with standard-dose pemetrexed for patients with advanced or metastatic NSCLC.

A randomized Phase III trial (LUME-Lung 2) was performed to evaluate nintedanib (200 mg twice daily) plus pemetrexed (500 mg/m^2^) in comparison with pemetrexed alone in white patients with advanced nonsquamous NSCLC after the failure of first-line therapy. However, as a result of futility at a prespecified interim analysis based on investigator-assessed progression-free survival (PFS), the primary end point of the study, this trial was initially stopped. A subsequent analysis of the available intent-to-treat population based on independent review data showed a PFS benefit for patients treated with nintedanib plus pemetrexed compared with placebo plus pemetrexed (median PFS of 4.4 months versus 3.6 months; hazard ratio \[HR\] of 0.83 with a 95% confidence interval \[CI\] of 0.70--0.99; *P*=0.04), but there was no difference in overall survival (OS) between the two arms. A higher incidence of elevated ALT (23% versus 7%) or AST (12% versus 2%) of grade ≥3 as well as of diarrhea of grade ≥3 (3% versus 1%) was apparent in patients treated with nintedanib and pemetrexed.[@b18-tcrm-11-1701]

Nintedanib in combination with docetaxel
----------------------------------------

A dose-escalation Phase I study assessing the safety and MTD of continuous daily treatment with nintedanib plus standard-dose docetaxel (75 mg/m^2^, every 3 weeks) and prednisone (5 mg twice daily) in European chemotherapy-naïve patients with metastatic hormone-refractory prostate cancer found that 200 mg twice daily was the recommended dose for nintedanib in this regimen.[@b19-tcrm-11-1701]

On the basis of the safety profile for this combination, a large Phase III trial (LUME-Lung 1) was conducted to evaluate docetaxel (75 mg/m^2^) plus nintedanib (200 mg twice daily) in comparison with docetaxel alone as second-line therapy for patients with advanced NSCLC.[@b20-tcrm-11-1701] PFS, the primary end point of the trial, was significantly improved in the docetaxel-plus- nintedanib group compared with the docetaxel-alone group (median of 3.4 months versus 2.7 months; HR of 0.79 with a 95% CI of 0.68--0.92; *P*=0.0019), and OS was significantly improved for patients with adenocarcinoma tumor histology (median of 12.6 months versus 10.3 months; HR of 0.83 with a 95% CI of 0.70--0.99; *P*=0.0359) but not for the total study population. Subgroup analysis of PFS according to demographic and baseline characteristics -- including sex, age, Eastern Cooperative Oncology Group performance status, and smoking status -- was consistent with the primary analysis, favoring the docetaxel-plus-nintedanib group, whereas patients registered in the study within 9 months after initiation of first-line chemotherapy appeared to derive greater benefit from docetaxel plus nintedanib compared with those registered ≥9 months after the onset of first-line treatment. These results indicated that nintedanib in combination with docetaxel is a potential option for patients who become refractory to first-line therapy within 9 months. Adverse events that were more common (≥10% difference for all grades) in the docetaxel-plus-nintedanib arm than in the docetaxel-plus-placebo arm included diarrhea (all grades, 42.3% versus 21.8%; grade ≥3, 6.6% versus 2.6%) as well as reversible increases in ALT (all grades, 28.5% versus 8.4%; grade ≥3, 7.8% versus 0.9%) and AST (all grades, 22.5% versus 6.6%; grade ≥3, 3.4% versus 0.5%). Most of these adverse events were manageable with supportive treatment or dose reduction. The incidence of adverse events commonly associated with antiangiogenic agents, such as hypertension (all grades, 3.5% versus 0.9%), bleeding (all grades, 14.1% versus 11.6%), thrombotic events (all grades, 5.1% versus 4.6%), and gastrointestinal perforation (all grades, 0.5% versus 0.5%), was similar in both groups. An adverse event leading to death possibly unrelated to disease progression was reported in 5.4% of patients in the docetaxel-plus-nintedanib group and in 3.8% of those in the docetaxel-plus-placebo group. This study is the first trial in the second-line setting to show a survival benefit for the combination of an antiangiogenic agent and chemotherapy in predefined NSCLC patients with adenocarcinoma tumor histology. On the basis of these results, nintedanib was approved by the European Union in November 2014 for the treatment of patients with advanced lung adenocarcinoma after the failure of first-line chemotherapy.

Another Phase III trial (LUME-Columbus) is currently in progress to investigate the efficacy and safety of combination treatment with nintedanib (200 mg twice daily) plus docetaxel (75 mg/m^2^) compared with placebo plus docetaxel (75 mg/m^2^) in individuals with advanced lung adenocarci-noma, including North American patients, after the failure of first-line chemotherapy ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier NCT02231164).

Docetaxel plus nintedanib in Japanese patients
----------------------------------------------

A dose-escalation Phase I study was also conducted to define the MTD of nintedanib plus docetaxel in Japanese patients with advanced NSCLC following the failure of first-line platinum-based chemotherapy ([Table 2](#t2-tcrm-11-1701){ref-type="table"}).[@b21-tcrm-11-1701] Eligible patients received 60 mg/m^2^ or 75 mg/m^2^ dose of docetaxel (day 1) plus 100 mg, 150 mg, or 200 mg doses of nintedanib twice daily (days 2--21) in 21-day cycles. No DLT was observed for the first (nintedanib at 100 mg twice daily plus docetaxel at 60 mg/m^2^) and second (nintedanib at 150 mg twice daily plus docetaxel at 60 mg/m^2^) cohorts; however, in the third cohort (nintedanib at 200 mg twice daily plus docetaxel at 60 mg/m^2^), all three patients developed DLTs (elevation of liver enzymes), and these three patients had a BSA of \<1.5 m^2^. The protocol was then amended as a result of a recommendation by the external Efficacy and Safety Review Committee based on this early observation of a high incidence of DLTs in patients with a BSA of \<1.5 m^2^. Subsequent dose escalations were performed separately in two patient cohorts with a BSA of \<1.5 m^2^ or ≥1.5 m^2^. Of 12 patients with a BSA of \<1.5 m^2^ treated with nintedanib at 150 mg twice daily plus docetaxel at either 60 mg/m^2^ (n=6) or 75 mg/m^2^ (n=6), three patients (two and one treated with docetaxel at 60 mg/m^2^ or 75 mg/m^2^, respectively) experienced DLTs (elevation of liver enzymes). Of 12 patients with a BSA of ≥1.5 m^2^ treated with nintedanib at 200 mg twice daily plus docetaxel at either 60 mg/m^2^ (n=6) or 75 mg/m^2^ (n=6), two patients treated with each docetaxel dose experienced DLTs (elevation of liver enzymes). The MTD of nintedanib was thus determined to be 150 mg and 200 mg twice daily combined with docetaxel at 75 mg/m^2^ in patients with a BSA of \<1.5 m^2^ or ≥1.5 m^2^, respectively.

At the time that the opportunity for Japanese patients to join the global LUME-Columbus Phase III trial was considered, the lack of tolerability of nintedanib at a dose of 200 mg twice daily in combination with docetaxel at 75 mg/m^2^ in patients with a BSA of \<1.5 m^2^ had not been demonstrated in the Japanese Phase I trial. Another Phase I study, an open-label safety run-in trial, is now planned to determine the appropriateness of nintedanib at a starting dose of 200 mg twice daily plus docetaxel at 75 mg/m^2^ for Japanese patients with a BSA of \<1.5 m^2^ and locally advanced or metastatic adenocarcinoma after the failure of first-line platinum-based chemotherapy ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier NCT02300298).

Conclusion
==========

A recent Phase III trial demonstrated that treatment with the combination of nintedanib and docetaxel resulted in a significant and clinically meaningful improvement in PFS and OS compared with docetaxel alone in predefined NSCLC patients with adenocarcinoma tumor histology. The combination had an acceptable and manageable safety profile, with no new or unexpected safety findings. There was a low incidence of class effects typically associated with antiangiogenic agents, such as hypertension, bleeding, perforation, and thromboembolism, which have been noted with other antiangiogenic agents in patients with NSCLC. Nintedanib in combination with docetaxel is thus a potential treatment option for patients with advanced NSCLC previously treated with one line of platinum-based therapy.
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###### 

Number of patients with DLTs (among evaluable patients) during the first course of nintedanib monotherapy in Phase I studies based in Germany[@b13-tcrm-11-1701] and Japan[@b14-tcrm-11-1701]

  Nintedanib dose (mg)   Germany[b](#tfn2-tcrm-11-1701){ref-type="table-fn"}                               Japan[b](#tfn2-tcrm-11-1701){ref-type="table-fn"}                                                                            
  ---------------------- --------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------
  50                     0/2                                                                               N/A                                                                                                                          N/A
  100                    0/1                                                                               N/A                                                                                                                          N/A
  150                    N/A                                                                               0/6                                                                                                                          0/3
  150+200                N/A                                                                               0/6                                                                                                                          N/A
  200                    1/8 (hepatotoxicity)                                                              1/6 (decline in CD4^+^ lymphocytes)                                                                                          3/12[a](#tfn1-tcrm-11-1701){ref-type="table-fn"} (hepatotoxicity)
  250                    1/6[a](#tfn1-tcrm-11-1701){ref-type="table-fn"} (decline in CD4^+^ lymphocytes)   1/13[a](#tfn1-tcrm-11-1701){ref-type="table-fn"} (nausea)                                                                    3/6 (hepatotoxicity)
  300                    2/5 (hepatotoxicity)                                                              4/5 (one with nausea and vomiting; one with decline in CD4^+^ lymphocytes and hepatotoxicity; and two with hepatotoxicity)   N/A
  450                    2/3 (hepatotoxicity)                                                              N/A                                                                                                                          N/A

**Notes:**

MTD.

Data present as the number of patients with DLTs/number of patients eligible for evaluation of DLTs.

**Abbreviations:** DLTs, dose-limiting toxicities; MTD, maximum tolerated dose; N/A, not applicable.

###### 

Number of patients with DLTs (among evaluable patients) during the first course of nintedanib combination therapy in Phase I studies based in North America[@b17-tcrm-11-1701] and Japan[@b21-tcrm-11-1701]

  Nintedanib dose (mg bid)   North America[b](#tfn5-tcrm-11-1701){ref-type="table-fn"}   Japan[b](#tfn5-tcrm-11-1701){ref-type="table-fn"}                                                                                            
  -------------------------- ----------------------------------------------------------- --------------------------------------------------- --------------------- ------------------------------------------------------------------ -----------------------------------------------------------------
  100                        1/6                                                         0/3                                                 N/A                   N/A                                                                N/A
  150                        1/6                                                         2/6 (BSA \<1.5 m^2^)                                0/3 (BSA ≥1.5 m^2^)   1/6 (BSA \<1.5 m^2^)[a](#tfn4-tcrm-11-1701){ref-type="table-fn"}   2/6 (BSA ≥1.5 m^2^)
  200                        3/12[a](#tfn4-tcrm-11-1701){ref-type="table-fn"}            3/3 (BSA \<1.5 m^2^)                                2/6 (BSA ≥1.5 m^2^)   N/A                                                                2/6 (BSA ≥1.5 m^2^)[a](#tfn4-tcrm-11-1701){ref-type="table-fn"}
  250                        2/2                                                         N/A                                                 N/A                   N/A                                                                N/A

**Notes:**

MTD.

Data present as the number of patients with DLTs/number of patients eligible for evaluation of DLTs.

**Abbreviations:** DLTs, dose-limiting toxicities; MTD, maximum tolerated dose; BSA, body surface area; N/A, not applicable.
